research Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.





